Publications | Lund University Publications

1 – 3 of 3

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/publication?embed=1&q=author%3D%22Riise%2C+Jon%22+or+(documentType+any+%22bookEditor+conferenceEditor%22+and+editor%3D%22Riise%2C+Jon%22)&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

2025
Mark Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH) : a randomised, open-label, phase 2/3 superiority trial
Lewis, David J ; Jerkeman, Mats ^LU ; Sorrell, Lexy ; Wright, David ; Glimelius, Ingrid ; Poulsen, Christian B. ; Pasanen, Annika ; Rawstron, Andrew C. ; Wader, Karin Fahl and Morley, Nick , et al. (2025) In The Lancet
- Contribution to journal › Article
2024
Mark MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma : the Nordic Lymphoma Group MCL7 VALERIA trial
Jerkeman, Mats ^LU ; Kolstad, Arne ; Hutchings, Martin ; Pasanen, Annika ; Meriranta, Leo ; Niemann, Carsten Utoft ; Jørgensen, Rasmus Rask Kragh ; El-Galaly, Tarec Christoffer ; Riise, Jon and Leppä, Sirpa , et al. (2024) In Blood Advances 8(2). p.407-415
- Contribution to journal › Article
Mark Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE) : a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
Dreyling, Martin ; Doorduijn, Jeanette ; Giné, Eva ; Jerkeman, Mats ^LU ; Walewski, Jan ; Hutchings, Martin ; Mey, Ulrich ; Riise, Jon ; Trneny, Marek and Vergote, Vibeke , et al. (2024) In The Lancet 403(10441). p.2293-2306
- Contribution to journal › Article